Albuterol sulfate
Pro Research Analysisby 
Searched over 200M research papers for "albuterol sulfate"
Albuterol Sulfate: Efficacy, Safety, and Applications
Introduction to Albuterol Sulfate
Albuterol sulfate is a widely used beta-2-adrenergic bronchodilator for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). It is available in various formulations, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), tablets, syrups, and nebulized solutions. This article synthesizes recent research on the efficacy, safety, and specific applications of albuterol sulfate.
Stereoselective Sulfation of Albuterol
Research has shown that the human hepatoma cell line Hep G2 can biosynthesize the sulfate conjugate of albuterol, with a clear preference for the sulfation of the pharmacologically active (-)-enantiomer over the (+)-enantiomer. This stereoselective sulfation results in a 7.8-fold higher efficiency for the (-)-enantiomer, suggesting higher bioavailability of the (+)-enantiomer after oral or inhaled doses .
Comparative Efficacy of HFA-134a and CFC Albuterol
With the phase-out of chlorofluorocarbon (CFC) propellants, the non-CFC propellant HFA-134a has been evaluated as a replacement. Studies comparing HFA-134a albuterol sulfate with conventional CFC albuterol in patients with asthma found no significant differences in bronchodilator efficacy or safety profiles between the two formulations. Both formulations showed significant dose responses in improving FEV1, serum potassium, heart rate, and blood pressure .
Extended-Release Albuterol in Pediatric Asthma
Extended-release albuterol sulfate tablets have been shown to be effective and well-tolerated in children aged 6 to 12 years with asthma. In a randomized, double-blind, placebo-controlled study, children receiving extended-release albuterol demonstrated significant improvements in pulmonary function and reduced asthma symptoms compared to placebo, with no serious treatment-related adverse events .
Albuterol Premedication in Pediatric Tonsillectomy
A randomized clinical trial investigated the use of inhaled albuterol sulfate as a premedication to reduce perioperative respiratory adverse events in children undergoing tonsillectomy. The study found that albuterol premedication significantly reduced the incidence of respiratory complications such as bronchospasm, laryngospasm, and oxygen desaturation compared to placebo, suggesting its potential benefit in pediatric surgical settings .
Aerosolized Albuterol Delivery in Neonates
A novel ventilator circuit/patient interface connector has been developed to improve the delivery of aerosolized albuterol sulfate in neonates under ventilatory support. In vitro evaluations demonstrated that this new connector significantly increased the delivery of albuterol and provided a particle size distribution more consistent with the nebulizer's output, compared to standard care .
Bioavailability and Pharmacokinetics of Albuterol Formulations
A study comparing the bioavailability of different oral formulations of albuterol sulfate (tablets and syrup) found that all formulations were rapidly absorbed, with comparable maximum drug concentrations and elimination half-lives. This suggests that the choice of formulation can be based on patient preference and convenience without compromising efficacy .
Dose-Ranging Studies of Albuterol MDI
Phase II studies assessed the efficacy and safety of a new albuterol sulfate MDI using Co-suspension Delivery™ Technology. The studies found that the new MDI was equivalent to Proventil® in terms of bronchodilation and safety, supporting its use in future clinical trials .
Comparative Efficacy of Albuterol Inhalers
A long-term study comparing the efficacy and safety of albuterol administered via a Spiros dry powder inhaler (DPI) and a metered-dose inhaler (MDI) found both methods to be equally effective in improving FEV1 in patients with asthma. Both treatments were well-tolerated, with no significant differences in adverse events .
Parenteral Albuterol in Asthma Treatment
Comparative studies of parenteral albuterol (intravenous, intramuscular, and subcutaneous) with subcutaneous epinephrine in adult asthmatic patients showed similar efficacy in improving FEV1 and comparable metabolic side effects, such as changes in serum potassium and glucose levels. This indicates that parenteral albuterol is a viable alternative to epinephrine for acute asthma management .
Albuterol and Magnesium Sulfate in Acute Asthma
A clinical trial evaluating the combination of nebulized magnesium sulfate and albuterol in adults with mild-to-moderate asthma exacerbations found no additional benefit over albuterol alone. This suggests that magnesium sulfate may not be necessary in such cases, although its efficacy in severe exacerbations remains to be determined .
Conclusion
Albuterol sulfate remains a cornerstone in the management of asthma and other respiratory conditions, with various formulations and delivery methods tailored to different patient needs. Ongoing research continues to optimize its efficacy and safety, ensuring its role as a critical therapeutic agent in respiratory care.
Sources and full results
Most relevant research papers on this topic
DOI
DOI